Table 3. Subgroup Univariate Analysis of Risk Factors Associated with Biliary Stent Patency in Patients Who Underwent Subsequent Biliary Stent Insertion after Duodenal Stent Insertion.
| Variable | Univariate | ||
|---|---|---|---|
| HR | 95% CI | P | |
| Age (year) | 0.603 | 0.143–2.537 | 0.490 |
| < 63 | |||
| ≥ 63 | |||
| Sex | 0.712 | 0.170–2.984 | 0.642 |
| Female | |||
| Male | |||
| Underlying malignancy | 1.941 | 0.390–9.666 | 0.418 |
| Periampullary cancer* | |||
| Metastatic cancer† | |||
| Level of extrahepatic biliary obstruction | |||
| Distal CBD | |||
| Proximal CBD | 0.406 | 0.101–1.627 | 0.203 |
| Whole CBD | 0.000 | 0.000 | 0.992 |
| Type of biliary stent | 3.660 | 0.425–31.530 | 0.238 |
| Uncovered | |||
| Covered | |||
| Location of distal end of biliary stent | 8.424 | 1.632–43.485 | 0.011 |
| Within duodenal stent | |||
| Beyond duodenal stent | |||
| Length of duodenal obstruction (mm) | 0.550 | 0.131–2.316 | 0.415 |
| < 57 | |||
| ≥ 57 | |||
| Approach route for duodenal stenting | 0.603 | 0.150–2.430 | 0.477 |
| Endoscopy | |||
| Fluoroscopy | |||
| Type of duodenal stent | 1.183 | 0.281–4.980 | 0.819 |
| Uncovered | |||
| Covered | |||
*Periampullary cancer includes pancreatic cancer, duodenal cancer, ampulla of Vater cancer, gallbladder cancer, and bile duct cancer, †Metastatic cancer includes gastric cancer, lung cancer, ovarian cancer, and ureter cancer.